**Supplementary Figure S2.**

Forest plot of TTD of the SF-36 health domains in patients with stage II–IIIA disease. The TTD analysis used clinically meaningful differences defined in the 2nd edition of the SF-36 scoring manual (32) and was performed using a log rank test stratified by stage (IB vs. II vs. IIIA), race (Asian vs. non-Asian) and mutation type (Ex19del vs. L858R). HRs and corresponding 95% CIs are shown for each health domain along with the number of events (n) in the overall population (N). A HR <1 favors osimertinib treatment. Calculated using the Kaplan Maier method. CI, confidence interval; SF-36, Short Form-36 health survey; TTD, time to deterioration.

